By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Threshold Pharmaceuticals, Inc. 

170 Harbor Way
Suite 300
South San Francisco  California  94080-6108  U.S.A.
Phone: 650-474-8200 Fax: 650-474-2529


SEARCH JOBS


Industry
Pharmaceutical






Company News
Threshold Pharmaceuticals, Inc. (THLD) Announces Initiation Of Dosing With TH-302/Bortezomib (Velcade(R))/Dexamethasone ("TBorD") In Final Stage Of Ongoing Phase 1/2 Trial Of Patients With Relapsed/Refractory Multiple Myeloma 7/9/2014 11:30:56 AM
Threshold Pharmaceuticals, Inc. (THLD) Initiates 440-Patient, Randomized, Double-Blind, Placebo-Controlled Trial Of TH-302 In Combination With Pemetrexed In Advanced Non-Squamous Non-Small Cell Lung Cancer 7/1/2014 11:12:38 AM
Threshold Pharmaceuticals, Inc. (THLD) Announces Presentation And Webcast At The Jefferies and Co. Global Healthcare Conference 6/2/2014 10:48:12 AM
Threshold Pharmaceuticals, Inc. (THLD) Announces Data From Ongoing Phase 1/2 Trial Of TH-302 Plus Bevacizumab (Avastin®) In Patients With Recurrent Glioblastoma 5/30/2014 9:41:14 AM
Threshold Pharmaceuticals, Inc. (THLD) Announces Data From Ongoing Phase 1/2 Trial Of TH-302 Plus Dexamethasone In Patients With Relapsed/Refractory Multiple Myeloma 5/30/2014 9:39:55 AM
Threshold Pharmaceuticals, Inc. (THLD) Announces Webcast of Analyst Event On Sunday, June 1, 2014 5/28/2014 10:41:19 AM
Threshold Pharmaceuticals, Inc. (THLD) Announces Clinical Data On TH-302 In Glioblastoma and Relapsed/Refractory Multiple Myeloma To Be Presented At American Society of Clinical Oncology 2014 5/15/2014 10:21:16 AM
Threshold Pharmaceuticals, Inc. (THLD) Announces Presentation And Webcast At The UBS Global Healthcare Conference 5/13/2014 10:10:23 AM
Threshold Pharmaceuticals, Inc. (THLD) CEO Named As Finalist For European Inventor Award 5/7/2014 9:24:39 AM
Threshold Pharmaceuticals, Inc. (THLD) Reports First Quarter 2014 Financial And Operational Results 5/1/2014 10:04:49 AM
12345678910...
//-->